Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
  1. 4 Open-market sale Chief Financial Officer sold 4,800 shares at an average $30.01 ($144,028)
  2. 4 Grant or award Director acquired 6,020 shares (grant or award)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Grant or award Director acquired 3,010 shares (grant or award)
  5. 4 Grant or award Director acquired 3,010 shares (grant or award)
  6. 4 Grant or award Director acquired 3,010 shares (grant or award)
  7. 4 Grant or award Director acquired 3,010 shares (grant or award)
  8. 4 Grant or award Director acquired 3,010 shares (grant or award)
  9. 4 Grant or award Director acquired 3,010 shares (grant or award)
  10. 4 Grant or award Director acquired 3,010 shares (grant or award)
  11. 4 Exercise or conversion Chief Financial Officer acquired 29,900 shares (option exercise)
  12. 4 Grant or award Chief Financial Officer acquired 8,900 shares (grant or award)
  13. 4 Shares withheld for taxes Chief Oper. & Tech. Officer gave up 1,332 shares (to pay taxes)
  14. 4 Open-market sale Chief Medical Officer sold 1,598 shares at $33.75 ($53,933)
  15. 4 Shares withheld for taxes Chief Scientific Officer gave up 1,221 shares (to pay taxes)
  16. 4 Shares withheld for taxes Chief Legal Officer gave up 1,332 shares (to pay taxes)
  17. 4 Shares withheld for taxes President and CEO gave up 3,636 shares (to pay taxes)
  18. 4 Open-market sale Director sold 112,869 shares at an average $34.69 ($3,915,359)
  19. 4 Gift President and CEO gave 3,300 shares (gift)
  20. 4 Open-market sale President and CEO sold 1,500 shares at $40.00 ($60,000)

Page 7 of 22 · 435 filings